•  
  •  
  •  
  •  

2026-05-28 22:34:16

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • The Sukhjit Starch and Chemicals Ltd delivers a Revenue Growth of 16.89% QoQ in Q4 FY26 with Optimistic Outlook
  • Power and Instrumentation Gujarat Ltd receives additional work order worth Rs. 7.13 crore
  • Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility
  • Kissht delivers first results post-listing: FY26 PAT up 75% YoY to ₹281 Cr; AUM crosses ₹7,000 Cr milestone
  • Likhitha Infrastructure Ltd receives order worth Rs. 121.04 crores

Keywords Selected:  INE935A01035

Stock Report

  • Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg
  • Glenmark Pharmaceuticals announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.
  • Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India
  • Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Glenmark Pharmaceuticals Inc., USA to launch Potassium Phosphates Injections
  • Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
  • Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
  • Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
  • Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
  • Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
  • Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
  • Glenmark Pharmaceuticals Announces Q2FY26 Results
  • Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership
  • Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
  • Glenmark Pharma arm receives upfront payment of $700 Mn from AbbVie
  • Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial

Latest Post

  • The Sukhjit Starch and Chemicals Ltd delivers a Revenue Growth of 16.89% QoQ in Q4 FY26 with Optimistic Outlook
  • Power and Instrumentation Gujarat Ltd receives additional work order worth Rs. 7.13 crore
  • Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility
  • Kissht delivers first results post-listing: FY26 PAT up 75% YoY to ₹281 Cr; AUM crosses ₹7,000 Cr milestone
  • Likhitha Infrastructure Ltd receives order worth Rs. 121.04 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025